Figure 2
From: DNA-launched RNA replicon vaccines induce potent anti-SARS-CoV-2 immune responses in mice
Anti-SARS-CoV-2 IgG antibody responses. (A) Schematic representation of the experiment schedule. C57BL/6 J mice (n = 5–20/group) were immunized once or twice with 10 μg of either DREP-S, DREP-Secto or Secto protein (P-Secto) and blood samples were collected three weeks after each immunization. Individual serum samples were assayed by ELISA using plates coated with SARS-CoV-2 spike (S) or receptor binding domain (RBD) antigens (B,D and C,E, respectively). The results are presented either as endpoint antibody titers (B,C) or EC50 values (D,E). Statistical analysis was performed using Kruskal Wallis test followed by Dunn’s test for multiple comparisons, *p < 0.05; **p < 0.01; ***p < 0.001, ****p < 0.0001. Comparisons that were non-significant are not indicated.
